Somatic PIK3R1 mutations in the iSH2 domain are accessible to PI3Kα inhibition
G Morin(Inserm), Guillaume Canaud(Hôpital Necker-Enfants Malades), Antoine Fraissenon(Université Claude Bernard Lyon 1), Florence Petit(Centre Hospitalier Universitaire de Lille), Laurent Guibaud(Hospices Civils de Lyon), Christine Broissand(Hôpital Necker-Enfants Malades), A. Dompmartin(Normandie Université), Vahid Asnafi(Hôpital Necker-Enfants Malades), Nicolas Goudin(Délégation Paris 5), P. Fayoux(Université de Lille), Estelle Balducci(Hôpital Necker-Enfants Malades), Christophe Legendre(Hôpital Necker-Enfants Malades), Chloé Quēlin(CIC Rennes), Alexandre P. Garneau(Inserm), Sophie Kaltenbach(Assistance Publique – Hôpitaux de Paris), Franck Mayeux(Hôpital Necker-Enfants Malades), Nabiha Bouzakher(Inserm), Sylvie Fraïtag(Délégation Paris 5), Amélie Blondel(Inserm), Christine Bodemer(Hôpital Necker-Enfants Malades), Patrick Villarèse(Université Paris Cité), Louise Ségot(Université Côte d'Azur), Caroline Chopinet(Centre Hospitalier Universitaire de Lille)
Cited by 2
Related Papers
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k
The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology
|American Journal of Transplantation|2016|625
The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery
|Cell|2016|563
Deep Dermatophytosis and Inherited CARD9 Deficiency
|New England Journal of Medicine|2013|403
Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing
|Clinical Pharmacology & Therapeutics|2010|363